

# GÖG COLLOQUIUM

DECEMBER 2021



## WHO Fair Pricing Forum

Dr. Kiusiang Tay-Teo

Department of Health Products Policy and Standards

Access to Medicines and Health Products

[www.who.int](http://www.who.int)

# A brief history of the forum



**Amsterdam  
May 2017**

**Johannesburg  
April 2019**




[www.who.int/publications/i/item/WHO-MVP-EMP-IAU-2019.09](http://www.who.int/publications/i/item/WHO-MVP-EMP-IAU-2019.09)



**WHA  
Resolution  
May 2019**

[apps.who.int/gb/ebwha/pdf\\_files/WHA72/A72\\_R8-en.pdf](https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R8-en.pdf)

**Virtual forum  
April 2021**  
Supported by  
government of Argentina



[www.who.int/publications/i/item/9789240038585](http://www.who.int/publications/i/item/9789240038585)

“ **Fair pricing** means pricing that allows for a reasonable return on investment in exchange for an affordable price, which is to say one that does not bankrupt health systems and other payers.

“ **Governments need to be enabled to play a stronger role** in negotiating prices and where appropriate, incentivising needs-based R&D

“ **The need for greater transparency** was a recognised as a recurring theme.

“ **Transparency** emerged as an end goal with broad consensus among stakeholders, although its exact definition and means of achieving it remain polarizing.

“ Participants acknowledged a **trust gap among stakeholders** that must be addressed to move forward. The Fair Pricing Forum can serve as an important convening mechanism to achieve this, but only if the dialogue can **move beyond traditional arguments and blanket statements to true collaboration** toward creative solutions.

“ OP2.5: “to continue WHO’s efforts to **biennially convene the Fair Pricing Forum** with Member States and all relevant stakeholders to discuss the **affordability and transparency of prices and costs** relating to health products.”

# 2021 FAIR PRICING FORUM in numbers



**150+**  
contributors



**1260+**

minutes of presentations  
and discussions



**850+**  
Registrants



**14**

Plenary and parallel sessions  
and pre-Forum webinar



**125**  
member states



++  
++

Offline attendees

# **Need for Global Public Goods and affordable access for all in the time of COVID-19 pandemic and beyond**

**1**

**Pricing transparency**

**2**

**Pricing approaches and pharmaceutical pricing policies**

**3**

**Aligning incentives for pharmaceutical innovation at fair prices**

**4**

**Public health-driven application and management of Intellectual property**

**5**

**Challenges for affordability of medical device and in vitro diagnostics**

**6**

**Judicialization in health care**

# Themes emerging from Forum discussion



**Transparency is essential for improving access to current and future innovations** as it is required for informing and enforcing pricing and innovation policies, as well as ensuring accountability

**Collaboration across countries** can facilitate affordable access

**Growing interests for public sector to play a greater role** in ensuring affordability and driving future innovations

**Need to clarify affordability**

**Need for developing policies to ensure affordable access to medical devices and in vitro diagnostics**